Grant: Project Grant - PA: Neurosciences, Mental Health and Addiction
Université Laval
$100,000.00
Endocrine drugs for symptomatic treatments in a monkey model of Parkinson's disease
FY 2025-26
Summary
Parkinson's disease, primarily affecting the elderly, is characterized by a loss of dopamine neurons in the brain. Its prevalence is expected to grow in the future due to the aging population. Parkinson's disease is well documented to be higher in men than in women and this sex difference could be due to effects of sex hormones. The dopamine precursor, L- Dopa, is the most effective pharmacotherapy for Parkinson's disease but a majority of patients develop motor complications associated with this treatment such as L-Dopa induced dyskinesias (involuntary movements) that are more prevalent in women. Amantadine is the most prescribed drug to treat dyskinesias but its presents with side effects. Estrogens show
antiparkinsonian and antidyskinetic activities in women with Parkinson's disease. The risk of cancer with estrogens and their feminizing effects in men has hampered their clinical use in
Parkinson's disease. Can these beneficial activities be optimized while reducing side-effects? This project will seek the effect of a selective estrogen receptor modulator used in women to
treat osteoporosis, raloxifene and DHED, a novel drug transformed into estradiol specifically in the brain. Modulating the synthesis and metabolism of steroids with specific inhibitors is shown to reduce dyskinesias in male rat model of Parkinson's disease and in men with Parkinson's disease to reduce dopaminergic-induced drug gambling. The inhibitor dutasteride is used safely in men to treat endocrine conditions. In a translational perspective for use in
men with Parkinson's disease, we will test the antidyskinetic activity of dutasteride in male parkinsoninan monkeys. This research in monkeys with endocrine drugs can translate to Parkinson's disease treatment in the short-term.
Department
Program
Project Grant - PA: Neurosciences, Mental Health and Addiction
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
554255
Name
Di Paolo-Chenevert Thérèse
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Behavioural Sciences - C: Behavioural Studies, Neuroscience and Cognition 2
Projecttitle
Endocrine drugs for symptomatic treatments in a monkey model of Parkinson's disease
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Neurosciences, Mental Health and Addiction
Keyworddelim
5-Alpha Reductase; Dyskinesia; Estrogen; Levodopa; Menopause; Monkey; Mptp; Neurosteroid; Parkinson; Raloxifene
Abstract
Parkinson's disease, primarily affecting the elderly, is characterized by a loss of dopamine neurons in the brain. Its prevalence is expected to grow in the future due to the aging population. Parkinson's disease is well documented to be higher in men than in women and this sex difference could be due to effects of sex hormones. The dopamine precursor, L- Dopa, is the most effective pharmacotherapy for Parkinson's disease but a majority of patients develop motor complications associated with this treatment such as L-Dopa induced dyskinesias (involuntary movements) that are more prevalent in women. Amantadine is the most prescribed drug to treat dyskinesias but its presents with side effects. Estrogens show
antiparkinsonian and antidyskinetic activities in women with Parkinson's disease. The risk of cancer with estrogens and their feminizing effects in men has hampered their clinical use in
Parkinson's disease. Can these beneficial activities be optimized while reducing side-effects? This project will seek the effect of a selective estrogen receptor modulator used in women to
treat osteoporosis, raloxifene and DHED, a novel drug transformed into estradiol specifically in the brain. Modulating the synthesis and metabolism of steroids with specific inhibitors is shown to reduce dyskinesias in male rat model of Parkinson's disease and in men with Parkinson's disease to reduce dopaminergic-induced drug gambling. The inhibitor dutasteride is used safely in men to treat endocrine conditions. In a translational perspective for use in
men with Parkinson's disease, we will test the antidyskinetic activity of dutasteride in male parkinsoninan monkeys. This research in monkeys with endocrine drugs can translate to Parkinson's disease treatment in the short-term.
Competitiondate
202509
Approvedterm2
1 yr 0 mth
Pinamesdelim
Di Paolo-Chenevert, Thérèse
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~